The product was developed in partnership with Diatech, which built its CE-IVD marked Myriapod® system and assays for molecular diagnostics based on Agena Bioscience’s MassARRAY technology.
#Agena bioscience san diego plus
The MassARRAY Dx PLUS assays intend to serve these unmet needs. However, the lack of a cost-effective, practical method for screening in parallel has complicated the ease of introducing new mutations into clinical testing. As personalized treatment has evolved with the discovery of new biomarkers, as well as the advent of novel cancer drugs, such as tyrosine kinase inhibitors, the number of actionable mutations has expanded. Labs can rapidly test for the most critical mutations in KRAS, NRAS, BRAF, EGFR, and ALK genes to drive better patient treatment outcomes.Ĭlinical practice guidelines, such as those set forth by the European Society of Medical Oncology, necessitate screening mutations in oncogenes such as EGFR and/or KRAS for targeted treatment. MassARRAY Dx PLUS assays will provide parallel analysis of the most frequently observed and actionable mutations in colon, lung, or melanoma tumors. The MassARRAY Dx PLUS assays improve upon existing methods on the market, enabling highly multiplexed screening of actionable targets in a single assay, thereby dramatically reducing cost and turnaround time for testing laboratories. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics. (Agena Bioscience 201407– CEO before Life Technologies + Applied Biosystems + Arcturus + Affymetrix)Īgena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. San Diego, CA.Īgena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srlĭansky, Peter M. "Press Release: Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment". Document › Details Agena Bioscience, Inc.
0 kommentar(er)
